

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/00	A2	(11) International Publication Number: WO 00/21512 (43) International Publication Date: 20 April 2000 (20.04.00)
(21) International Application Number: PCT/US99/21437 (22) International Filing Date: 6 October 1999 (06.10.99) (30) Priority Data: 09/169,608 9 October 1998 (09.10.98) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (72) Inventors: ASLANIAN, Robert, G.; 144 Philip Drive, Rockaway, NJ 07866 (US). PIWINSKI, John, J.; 6 Saddle Ridge Drive, Clinton Township, NJ 08833 (US). (74) Agents: KALYANARAMAN, Palaiyur, S. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES (57) Abstract The present invention is directed towards a pharmaceutical composition useful for the treatment of allergic rhinitis, asthma and related disorders. In one embodiment, the compositions comprises, in combination, a therapeutically effective amount of at least one neurokinin antagonist, a therapeutically effective amount of at least one H ₃ antagonist and a therapeutically effective amount of at least one H ₁ antagonist.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES

5 FIELD OF THE INVENTION

The present invention generally relates to compositions and methods for treating allergic rhinitis and other respiratory diseases. It specifically discloses compositions which comprise combinations of antagonists of neurokinin receptors and antagonists of histamine receptors, and methods
10 for treating the above-noted diseases with such compositions.

BACKGROUND OF THE INVENTION

Neurokinin receptors such as the NK₁ and the NK₂ receptors are found in the central nervous system, the circulatory system, and the
15 peripheral tissues of mammals, and are involved in a variety of biological processes. Antagonists of the neurokinin receptors are, therefore, expected to be useful in the treatment or prevention of various mammalian diseases such as, for example, pulmonary disorders such as asthma, cough, bronchospasm, chronic obstructive pulmonary diseases, and airway
20 hyperactivity; skin disorders and itch, for example, atopic dermatitis, and cutaneous wheal and flare; neurogenic inflammatory diseases such as, arthritis, migraine, nociception; CNS diseases such as anxiety, emesis, Parkinson's disease, movement disorders and psychosis; convulsive disorders, renal disorders, urinary incontinence, ocular inflammation,,
25 inflammatory pain, and eating disorders such as food intake inhibition; allergic rhinitis, neurodegenerative disorders, psoriasis, Huntington's disease, depression and various disorders such as Crohn's disease. NK₁ receptors have been reported to be involved in microvascular leakage and mucus secretion, and NK₂ receptors have been associated with smooth
30 muscle contraction, making NK₁ and NK₂ receptor antagonists especially useful in the treatment and prevention of asthma. NK₁ and NK₂ receptor antagonists have been reported such as, for example, in U.S. patents 5,798,359; 5,795,894; 5,789,422; 5,783,579; 5,719,156; 5,696,267; 5,691,362; 5,688,960; 5,654,316; and in "Recent Advances in Neurokinin
35 Receptor Antagonists", by C. J. Ohnmacht Jr., *et al*, *Annual Reports in Medicinal Chemistry*, A. M. Doherty Ed., 33, 71-80 (1998).

and related disorders is well known. A discussion is provided by, for example, R. Aslanian *et al*, *Exp.Opin.Ther.Patents*, 7(3), 201-207 (1997) as well as in references cited therein.

5 The discovery of the H₃ receptor is a fairly recent phenomenon. The H₃ receptor is most abundantly distributed in the CNS, and in lesser amounts in peripheral tissues. The H₃ receptor is considered an important general neuroregulatory mechanism for various physiological processes, not only in the CNS but in peripheral tissues as well. A discussion of the H₃ receptor and antagonists therefor can be found in J. G. Phillips *et al*, *Annual Reports in Medicinal Chemistry*, J. Bristol, ed., 33, 31-40 (1998).

15 Compounds that antagonize both the NK₁ and H₁ receptors are disclosed, for example, in WO 96-06094 (Marion Merrell Dow, 1996). Dual antagonists of the H₁ and H₃ receptors are discussed, for example, in pending U.S. patent application, Serial No. 08/909,319, filed August 14, 1997. Pending U.S. patent application, Serial No. 60/068,638, filed December 23, 1997, discloses compositions comprising leukotriene antagonists and H₁ receptors.

20 It would be highly desirable to enhance the efficacy of the neurokinin antagonists to improve their overall efficacy.

SUMMARY OF THE INVENTION

25 The afore-mentioned objective and other objectives and desires are addressed by the present invention which, in one embodiment, provides a composition for treating and preventing allergic rhinitis and other respiratory diseases such as asthma, cough, wheezing and the like. The inventive composition comprises: (i) a therapeutically effective amount of at least one neurokinin antagonist; (ii) a therapeutically effective amount of at least one H₃ antagonist and (iii) a therapeutically effective amount of at least one H₁ antagonist. One or more of the antagonists may be substituted by a pharmaceutically acceptable derivative such as salt, ester, and the like, if so desired. Optionally, the composition may additionally contain a

30 pharmaceutically acceptable carrier, a decongestant (such as, for example, pseudoephedrine), a cough suppressant (such as, for example, dextromethorphan), expectorant (such as, for example, guaifenesin),

35

analgesics (such as, for example, aspirin, ibuprofen and acetaminophen) or mixtures thereof.

5 Generally, the amount of the neurokinin antagonist content in the inventive composition is about 1-1,000 milligrams, preferably about 10-500 milligrams, and typically about 50-200 milligrams. The amount of the H₃ antagonist is generally about 1-1,000 milligrams, preferably about 1-500 milligrams, and typically about 1-50 milligrams. The amount of the H₁ antagonist is generally about 1-200 milligrams, preferably about 1-100
10 milligrams, and typically about 2-10 milligrams.


The invention further provides a method for treating asthma and allergic disorders, sneezing, itching runny nose, nasal congestion, redness of the eye, tearing, itching of the ears or palate, sinusitis, and coughs
15 associated with postnasal drip symptoms in a mammalian organism in need of such treatment comprising administering a pharmaceutical composition as described above.

DETAILED DESCRIPTION OF THE INVENTION


20 In one embodiment, the present invention discloses pharmaceutical compositions that are useful in treating and preventing allergic rhinitis, asthma and related disorders. The composition comprises, in combination, a therapeutically effective amount of at least one neurokinin antagonist, a therapeutically effective amount of at least one H₃ antagonist and a
25 therapeutically effective amount of at least one H₁ antagonist. One or more of the antagonists may be substituted by a pharmaceutically acceptable derivative such as salt (such as, for example, hydrochloride), ester, and the like.

Several neurokinin antagonists that are currently known are useful in
30 the practice of the present invention. Non-limiting examples of such useful neurokinin antagonists include, for example, those belonging to the chemical class of oximes, hydrazones, piperidines, piperazines, aryl alkyl amines, hydrazones, nitroalkanes, amides, isoxazolines, quinolines, isoquinolines, azanorbornanes, naphthyridines, benzodiazepines and the
35 like. Many are disclosed in the U.S. patents cited earlier in this patent application. Preferred NK antagonists are those disclosed in the above-noted U.S. patents 5,798,359; 5,795,894; 5,789,422; 5,783,579; 5,719,156;


5,696,267; 5,691,362; 5,688,960; 5,654,316. The general formula of some of so-disclosed compounds is:



wherein Z is



or



where B is OR_2 ; NR_6COR_2 , $CONR_6R_7$ or $NR_2CONR_6R_7$,

$m=0$ or 1 ,

P is R_5 -aryl; or R_5 -heteroaryl; and

10 Y is H, $CR_2R_3CO_2R_6$; $CR_2R_3CONR_6R_7$ or $CR_2R_3NR_6COR_2$;

$a = b = 0, 1$ or 2 ;

Q has the same definitions as P above, with the proviso that P and Q may be the same or different;

A is $=N-OR_1$; $=N-NR_2R_3$; or $=CR_1R_2$;

15 X is $-O-$; $-NR_6-$; $-N(R_6)CO-$; or $-CO-NR_6-$;

T is R_4 -aryl; R_4 -heteroaryl; R_4 -cycloalkyl; or R_2 -bridged cycloalkyl;

R_1 is H, C_1 - C_6 alkyl; or $(CH_2)_n-G$ where $n=1-6$,

G is H; R_4 -aryl; R_4 -heteroaryl; COR_6 ; CO_2R_6 ; $CONR_6R_7$; CN; $OCOR_6$; SO_3R_2 ;

$C(=NOR_2)NR_6R_7$; $C(=NR_2)NR_6R_7$, with the proviso that when $n \neq 1$, G can

20 additionally be OR_6 , NR_6R_7 or $NR_6(CO)R_7$;


R_2 and R_3 are independently H or C_1 - C_6 alkyl;

R_4 and R_5 are independently 1, 2 or 3 substituents independently selected from OR_2 , $OC(O)R_2$, $OC(O)NR_6R_7$, C_1 - C_6 alkyl, H, halogen, CF_3 , C_2F_5 , or OCF_3 ; and


25 R_6 and R_7 are independently selected from H or C_1 - C_6 alkyl, with the proviso that when R_6 and R_7 are part of NR_6R_7 then said NR_6R_7 may form part of a C_5 - C_6 ring wherein 0-2 ring members are selected from the group consisting of $-O-$, $-S-$ and $-NR_2-$, with the further proviso that said C_5 - C_6 ring may contain substituents on said ring with said substituents being selected from the

30 group consisting of hydrogen, halogen, $-OR_6$ and $-COOR_6$.


Particularly preferred neurokinin antagonists are those disclosed in the above-mentioned U.S. patents and belonging to the general formula:



- 5 and stereoisomers thereof. More particularly preferred are the stereoisomers with the general formula:




where R is H, CH₂CONH₂, CH₂CONHMe, CH₂CONMe₂ or



- 10 The currently known H₃ receptor antagonists cannot be easily classified chemically. Illustrative H₃ receptor antagonists useful in the practice of the present invention include, without limitation, thioperamide (technical name: N-cyclohexyl-4-(1H-imidazol-4-yl)-1-

piperidinecarbothioamide, CAS Registry Number: 106243-16-7),
impromidine (technical name: N-[3-(1H-imidazol-4-yl)propyl]-N'-[2-[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine, CAS Registry Number:
65573-02-6), burimamide (technical name: N-[4-(1H-imidazol-4-yl)butyl]-N'-
5 methylthiourea, CAS Registry Number: 55720-27-9), clobenpropit (technical
name: [(4-chlorophenyl)methyl]-3-(1H-imidazol-4-yl)propyl ester of
carbamimidothioic acid, CAS Registry Number: 145231-45-4), impentamine,
mifetidine, S-sopromidine (technical name: N-[2-(1H-imidazol-4-yl)-1-
methylethyl]-N'-[2-[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine,
10 CAS Registry Number: 99616-14-5), R-sopromidine (CAS Registry Number:
79313-75-0), SKF-91486 (technical name: [3-(1H-imidazol-4-
yl)propyl]guanidine, CAS Registry Number: 46129-28-6), GR-175737 (CAS
Registry Number: 203874-78-6), GT-2016 (CAS Registry Number: 152241-
24-2), GT-2331, UCL-1199 (technical name: 2-[[2-(1H-imidazol-4-
15 yl)ethyl]thio]-5-nitropyridine, CAS Registry Number: 152030-16-5), 1H-
imidazole-4-pentanamine (CAS Registry Number: 34973-91-6), clozapine
(technical name: 8-chloro-11-(4-methyl-1-piperazinyl)-5H-
dibenzo[b,e][1,4]diazepine, CAS Registry Number: 54241-01-9) and the
compound N-(3,5-dichlorophenyl)-N'-[[4-[(1H-imidazol-
20 4-yl)methyl]phenyl]methyl]urea, and whose structure is shown below:



Certain benzamidines and benzylamidines as H₃ antagonists have been
described by R. Aslanian *et al*, *Bioorganic & Medicinal Chemistry*, 8, 2263-
25 2268 (1998). Other compounds can readily be evaluated to determine
activity at H₃ receptors by known methods, including, for example, the
guinea pig brain membrane assay and the guinea pig neuronal ileum
contraction assay, both of which are described in U.S. patent 5,352,707.
Another useful assay utilizes rat brain membranes and is described by West
30 *et al*, "Identification of Two H₃-Histamine Receptor Subtypes", *Molecular
Pharmacology*, 33, 610-613 (1990).

Numerous chemical substances are known to have histamine H₁ receptor antagonist activity. Many such compounds can be classified broadly as ethanolamines, ethylenediamines, alkylamines, phenothiazines, piperidines, and the like. Illustrative H₁ receptor antagonists useful in the practice of the present invention include, without limitation, astemizole, ceterizine, azatadine, azelastine, acrivastine, brompheniramine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine (also known as desloratadine or "DCL"), doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, normethylastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine, and tripolidine. Other compounds can readily be evaluated to determine activity at H₁ receptors by known methods including, for example, specific blockade of the contractile response to histamine of isolated guinea pig ileum.

In a further embodiment, this invention discloses a method for treatment of asthma, allergic rhinitis, and other allergic disorders, sneezing, itching runny nose, nasal congestion, redness of the eye, tearing, itching of the ears or palate, wheezing, sinusitis, and coughs associated with postnasal drip symptoms in a mammalian organism in need of such treatment comprising administering a pharmaceutical composition which comprises the neurokinin antagonist, H₃ antagonist and the H₁ antagonist as described above.

In the pharmaceutical compositions and methods of the present invention, the active ingredients will typically be administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as carrier materials) suitably selected with respect to the intended form of administration, i.e. oral tablets, capsules (either solid-filled, semi-solid filled or liquid filled), powders for constitution, oral gels, elixirs, dispersible granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices. For example, for oral administration in the form of tablets or capsules, the active drug component may be combined with any oral non-toxic pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and

the like. Moreover, when desired or needed, suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated in the mixture. Powders and tablets may be comprised of from about 5 to about 95 percent inventive composition. Suitable binders include starch, gelatin, 5 natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. Among the lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include starch, methylcellulose, guar gum and the like. 10 Sweetening and flavoring agents and preservatives may also be included where appropriate. Some of the terms noted above, namely disintegrants, diluents, lubricants, binders and the like, are discussed in more detail below.

Additionally, the compositions of the present invention may be 15 formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects, i.e. neurokinin antagonism, antihistaminic activity and the like. Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release 20 polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.

Liquid form preparations include solutions, suspensions and 25 emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injections or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.

30 Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.

35 For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing.

The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.

Also included solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally. The transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as a re conventional in the art for this purpose.

Preferably the compound is administered orally.

Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.

The quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 0.01 milligrams to about 1,000 milligrams, preferably from about 0.01 to about 750 milligrams, more preferably from about 0.01 to about 500 milligrams, and typically from about 0.01 to about 250 milligrams, according to the particular application. The actual dosage employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art. Generally, the human oral dosage form containing the active ingredients can be administered 1 or 2 times per day. The amount and frequency of the administration will be regulated according to the judgment of the attending clinician. A generally recommended daily dosage regimen for oral administration may range from about 0.04 milligrams to about 4,000 milligrams per day, in single or divided doses.

Capsule - refers to a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or

containing compositions comprising the active ingredients. Hard shell capsules are typically made of blends of relatively high gel strength bone and pork skin gelatins. The capsule itself may contain small amounts of dyes, opaquing agents, plasticizers and preservatives.

5

Tablet- refers to a compressed or molded solid dosage form containing the active ingredients with suitable diluents. The tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or by compaction.

10

Oral gels-refers to the active ingredients dispersed or solubilized in a hydrophillic semi-solid matrix.

15

Powders for constitution refers to powder blends containing the active ingredients and suitable diluents which can be suspended in water or juices.

20

Diluent - refers to substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn rice and potato; and celluloses such as microcrystalline cellulose. The amount of diluent in the composition can range from about 10 to about 90% by weight of the total composition, preferably from about 25 to about 75%, more preferably from about 30 to about 60% by weight, even more preferably from about 12 to about 60%.

25

Disintegrants - refers to materials added to the composition to help it break apart (disintegrate) and release the medicaments. Suitable disintegrants include starches; "cold water soluble" modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose; microcrystalline celluloses and cross-linked microcrystalline celluloses such as sodium croscarmellose; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures. The amount of disintegrant in the composition can range from about 2 to about 15% by weight of the composition, more preferably from about 4 to about 10% by weight.

35

Binders - refers to substances that bind or "glue" powders together and make them cohesive by forming granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose; starches derived from wheat, corn rice and potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate; cellulosic materials such as methylcellulose and sodium carboxymethylcellulose and hydroxypropylmethylcellulose; polyvinylpyrrolidone; and inorganics such as magnesium aluminum silicate. The amount of binder in the composition can range from about 2 to about 20% by weight of the composition, more preferably from about 3 to about 10% by weight, even more preferably from about 3 to about 6% by weight.

Lubricant - refers to a substance added to the dosage form to enable the tablet, granules, etc. after it has been compressed, to release from the mold or die by reducing friction or wear. Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; high melting point waxes; and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and d,l-leucine. Lubricants are usually added at the very last step before compression, since they must be present on the surfaces of the granules and in between them and the parts of the tablet press. The amount of lubricant in the composition can range from about 0.2 to about 5% by weight of the composition, preferably from about 0.5 to about 2%, more preferably from about 0.3 to about 1.5% by weight.

Glidants - materials that prevent caking and improve the flow characteristics of granulations, so that flow is smooth and uniform. Suitable glidants include silicon dioxide and talc. The amount of glident in the composition can range from about 0.1% to about 5% by weight of the total composition, preferably from about 0.5 to about 2% by weight.

Coloring agents - excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes and food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide. The amount of the coloring agent can vary from about 0.1 to about 5% by weight of the composition, preferably from about 0.1 to about 1%.

Bioavailability - refers to the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control.

5 Conventional methods for preparing tablets are known. Such methods include dry methods such as direct compression and compression of granulation produced by compaction, or wet methods or other special procedures. Conventional methods for making other forms for administration such as, for example, capsules, suppositories and the like are also well
10 known.

 It will be apparent to those skilled in the art that many modifications, variations and alterations to the present disclosure, both to materials and methods, may be practiced. Such modifications, variations and alterations
15 are intended to be within the spirit and scope of the present invention.

CLAIMS

What is claimed is:


1. A pharmaceutical composition comprising, in combination, a
5 therapeutically effective amount of at least one neurokinin antagonist or a pharmaceutically acceptable derivative thereof; a therapeutically effective amount of at least one H₃ antagonist or a pharmaceutically acceptable derivative thereof; and a therapeutically effective amount of at least one H₁ antagonist or a pharmaceutically acceptable derivative thereof.
- 10 2. The pharmaceutical composition of claim 1, wherein said neurokinin antagonist or its pharmaceutically acceptable derivative is present in amounts of 1-1,000 milligrams per unit dosage of said pharmaceutical composition.
- 15 3. The pharmaceutical composition of claim 1, wherein said neurokinin antagonist or its pharmaceutically acceptable derivative is present in amounts of 10-500 milligrams per unit dosage of said pharmaceutical composition.
- 20 4. The pharmaceutical composition of claim 1, wherein said neurokinin antagonist or its pharmaceutically acceptable derivative is present in amounts of 50-200 milligrams per unit dosage of said pharmaceutical composition.
- 25 5. The pharmaceutical composition of claim 1, wherein said H₃ antagonist or its pharmaceutically acceptable derivative is present in amounts of 1-1,000 milligrams per unit dosage of said pharmaceutical composition.
6. The pharmaceutical composition of claim 1, wherein said H₃ antagonist or its pharmaceutically acceptable derivative is present in amounts of 1-500 milligrams per unit dosage of said pharmaceutical composition.
- 30 7. The pharmaceutical composition of claim 1, wherein said H₃ antagonist or its pharmaceutically acceptable derivative is present in amounts of 1-50 milligrams per unit dosage of said pharmaceutical composition.

8. The pharmaceutical composition of claim 1, wherein said H₁ antagonist or its pharmaceutically acceptable derivative is present in amounts of 1-200 milligrams per unit dosage of said pharmaceutical composition.


5 9. The pharmaceutical composition of claim 1, wherein said H₁ antagonist or its pharmaceutically acceptable derivative is present in amounts of 1-100 milligrams per unit dosage of said pharmaceutical composition.

10 10. The pharmaceutical composition of claim 1, wherein said H₁ antagonist or its pharmaceutically acceptable derivative is present in amounts of 2-10 milligrams per unit dosage of said pharmaceutical composition.

15 11. The pharmaceutical composition of claim 1, wherein said neurokinin antagonist is a compound having the general formula:



wherein Z is



20 where B is OR₂; NR₆COR₂, CONR₆R₇ or NR₂CONR₆R₇,
m=0 or 1,

P is R₅-aryl; or R₅-heteroaryl; and

Y is H, CR₂R₃CO₂R₆; CR₂R₃CONR₆R₇ or CR₂R₃NR₆COR₂;

a= b= 0, 1 or 2;

25 Q has the same definitions as P above, with the proviso that P and Q may be the same or different;

A is =N-OR₁; =N-NR₂R₃; or =CR₁R₂;

X is -O-; -NR₆-; -N(R₆)CO-; or -CO-NR₆-;

T is R_4 -aryl; R_4 -heteroaryl; R_4 -cycloalkyl; or R_2 -bridged cycloalkyl;

R_1 is H, C_1 - C_6 alkyl; or $(CH_2)_n$ -G where $n=1-6$,

G is H; R_4 -aryl; R_4 -heteroaryl; COR_6 ; CO_2R_6 ; $CONR_6R_7$; CN; $OCOR_6$; SO_3R_2 ;

$C(=NOR_2)NR_6R_7$; $C(=NR_2)NR_6R_7$, with the proviso that when $n \neq 1$, G can

5 additionally be OR_6 , NR_6R_7 or $NR_6(CO)R_7$;


R_2 and R_3 are independently H or C_1 - C_6 alkyl;

R_4 and R_5 are independently 1, 2 or 3 substituents independently selected from OR_2 , $OC(O)R_2$, $OC(O)NR_6R_7$, C_1 - C_6 alkyl, H, halogen, CF_3 , C_2F_5 , or OCF_3 ; and


10 R_6 and R_7 are independently selected from H or C_1 - C_6 alkyl, with the proviso that when R_6 and R_7 are part of NR_6R_7 then said NR_6R_7 may form part of a C_5 - C_6 ring wherein 0-2 ring members are selected from the group consisting of -O-, -S- and $-NR_2$ -, with the further proviso that said C_5 - C_6 ring may contain substituents on said ring with said substituents being selected from the

15 group consisting of hydrogen, halogen, $-OR_6$ and $-COOR_6$.


12. The pharmaceutical composition of claim 1, wherein said neurokinin antagonist is a compound having the general formula:




20 and stereoisomers thereof, wherein $R=H$; CH_2CONH_2 ; $CH_2CONHMe$; CH_2CONMe_2 or



13. The pharmaceutical composition of claim 1, wherein said neurokinin antagonist is a compound having the general formula:



where R is H; CH₂CONH₂; CH₂CONHMe; or



5

14. The pharmaceutical composition of claim 13, wherein said neurokinin antagonist has $R=CH_2CONH_2$.

15. The pharmaceutical composition of claim 1, wherein said H₃ antagonist is selected from the group consisting of impromidine, burimamide, clobenpropit, impentamine, mifetidine, thioperamide, S-sopromidine, R-sopromidine, SKF-91486, GR-175737, GT-2016, GT-2331, UCL-1199, 1H-imidazole-4-pentanamine, clozapine and N'-[(3,5-dichlorophenyl)-N'-[[4-[(1H-imidazol-4-yl)methyl]phenyl]methyl]urea.

16. The pharmaceutical composition of claim 15, wherein said H₃ antagonist is N-(3,5-Dichlorophenyl)-N'-[[4-[(1H-imidazol-4-yl)methyl]phenyl]methyl]urea.

17. The pharmaceutical composition of claim 15, wherein said H₃ antagonist is GT-2331.


18. The pharmaceutical composition of claim 1, wherein said H₁ antagonist is an ethanolamine, ethylenediamine, alkylamine, phenothiazine or piperidine.

19. The pharmaceutical composition of claim 1, wherein said H₁ antagonist is selected from the group consisting of ceterizine, astemizole,

- azatadine, azelastine, acrivastine, brompheniramine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine, and tripolidine.


20. The pharmaceutical composition of claim 19, wherein said H_1 antagonist is loratadine.
21. The pharmaceutical composition of claim 19, wherein said H_1 antagonist is descarboethoxyloratadine.
22. The pharmaceutical composition of claim 1, additionally containing one or more materials selected from the group consisting of a pharmaceutically acceptable carrier, a decongestant, a cough suppressant and an expectorant.
23. A method for the treatment of asthma, allergic rhinitis, sneezing, itching runny nose, nasal congestion, redness of the eye, tearing, itching of the ears or palate, wheezing, coughs associated with postnasal drip symptoms and respiratory disorders associated with allergy in a mammalian organism in need of such treatment, said treatment comprising: administering a pharmaceutical composition comprising, in combination, a therapeutically effective amount of at least one neurokinin antagonist or a pharmaceutically acceptable derivative thereof; a therapeutically effective amount of at least one H_3 antagonist or a pharmaceutically acceptable derivative thereof; and a therapeutically effective amount of at least one H_1 antagonist or a pharmaceutically acceptable derivative thereof.

24. The method of claim 23, wherein said neurokinin antagonist is a compound having the general formula:



30

wherein Z is



where B is OR_2 ; NR_6COR_2 , $CONR_6R_7$ or $NR_2CONR_6R_7$,

$m=0$ or 1 ,

5 P is R_5 -aryl; or R_5 -heteroaryl; and

Y is H, $CR_2R_3CO_2R_6$; $CR_2R_3CONR_6R_7$ or $CR_2R_3NR_6COR_2$;

$a = b = 0, 1$ or 2 ;

Q has the same definitions as P above, with the proviso that P and Q may be the same or different;

10 A is $=N-OR_1$; $=N-NR_2R_3$; or $=CR_1R_2$;

X is $-O-$; $-NR_6-$; $-N(R_6)CO-$; or $-CO-NR_6-$;

T is R_4 -aryl; R_4 -heteroaryl; R_4 -cycloalkyl; or R_2 -bridged cycloalkyl;

R_1 is H, C_1-C_6 alkyl; or $(CH_2)_n-G$ where $n=1-6$,

G is H; R_4 -aryl; R_4 -heteroaryl; COR_6 ; CO_2R_6 ; $CONR_6R_7$; CN; $OCOR_6$; SO_3R_2 ;

15 C($=NOR_2$) NR_6R_7 ; C($=NR_2$) NR_6R_7 , with the proviso that when $n \neq 1$, G can additionally be OR_6 , NR_6R_7 or $NR_6(CO)R_7$;

R_2 and R_3 are independently H or C_1-C_6 alkyl;


R_4 and R_5 are independently 1, 2 or 3 substituents independently selected from OR_2 , $OC(O)R_2$, $OC(O)NR_6R_7$, C_1-C_6 alkyl, H, halogen, CF_3 , C_2F_5 , or OCF_3 ;

20 and


R_6 and R_7 are independently selected from H or C_1-C_6 alkyl, with the proviso that when R_6 and R_7 are part of NR_6R_7 then said NR_6R_7 may form part of a C_5-C_6 ring wherein 0-2 ring members are selected from the group consisting of -

25 O-, -S- and $-NR_2-$, with the further proviso that said C_5-C_6 ring may contain substituents on said ring with said substituents being selected from the group consisting of hydrogen, halogen, $-OR_6$ and $-COOR_6$.


25. The method of claim 23, wherein said neurokinin antagonist is a compound having the general formula:




where R=H; CH₂CONH₂; CH₂CONHMe; CH₂CONMe₂ or



26. The method of claim 23, wherein said neurokinin antagonist is a
5 compound having the general formula:



where R is H; CH₂CONH₂; CH₂CONHMe; CH₂CONMe₂; or



27. The method of claim 26, wherein said neurokinin antagonist is the
10 compound with R= CH₂CONHMe.

28. The method of claim 23, wherein said H₃ antagonist is selected from the group consisting of thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, S-sopromidine, R-sopromidine, SKF-91486, GR-175737, GT-2016, , GT-2331, UCL-1199, 1H-imidazole-4-
5 pentanamine, clozapine, and N-(3,5-dichlorophenyl)-N'-[[4-[(1H-imidazol-4-yl)methyl]phenyl]methyl]urea.

29. The method of claim 28, wherein said H₃ antagonist is N-(3,5-dichlorophenyl)-N'-[[4-[(1H-imidazol-4-yl)methyl]phenyl]methyl]urea .

30. The method of claim 23, wherein said H₁ antagonist is selected from
10 the group consisting of ceterizine, astemizole, azatadine, azelastine, acrivastine, brompheniramine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine,
15 mequitazine, mianserin, noberastine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine, and tripolidine.

31. The method of claim 30, wherein said H₁ antagonist is loratadine.

32. The method of claim 30, wherein said H₁ antagonist is
20 descarboethoxyloratadine.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/445, 45/06, A61P 11/06 // (A61K 31/445, 31:00)	A3	(11) International Publication Number: WO 00/21512 (43) International Publication Date: 20 April 2000 (20.04.00)
(21) International Application Number: PCT/US99/21437 (22) International Filing Date: 6 October 1999 (06.10.99) (30) Priority Data: 09/169,608 9 October 1998 (09.10.98) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (72) Inventors: ASLANIAN, Robert, G.; 144 Philip Drive, Rockaway, NJ 07866 (US). PIWINSKI, John, J.; 6 Saddle Ridge Drive, Clinton Township, NJ 08833 (US). (74) Agents: KALYANARAMAN, Palaiyur, S. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 6 July 2000 (06.07.00)	
(54) Title: COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES (57) Abstract <p>The present invention is directed towards a pharmaceutical composition useful for the treatment of allergic rhinitis, asthma and related disorders. In one embodiment, the compositions comprises, in combination, a therapeutically effective amount of at least one neurokinin antagonist, a therapeutically effective amount of at least one H₃ antagonist and a therapeutically effective amount of at least one H₁ antagonist.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/US 99/21437

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/445 A61K45/06 A61P11/06
/(A61K31/445, 31:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 98 06394 A (SCHERING CORP) 19 February 1998 (1998-02-19) page 3, line 30-32 page 4, line 17-29 page 5, line 1-5 page 6, line 23-27 page 8, line 20-32 page 13; example 9 page 12; example 6</p> <p style="text-align: center;">--- -/--</p>	1-32

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 April 2000

Date of making of the international search report

09/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Brunnauer, H

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/US 99/21437

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KUDLACZ E ET AL: "A role for histamine and substance P in immediate allergic responses in guinea pig airways: characterization of MDL 108,207DA, a dual H ₁ /NK-1 receptor antagonist." INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, (1998 FEB) 115 (2) 169-78.. XP000885972 abstract page 176, right-hand column	1-32
Y	WO 96 06094 A (MERRELL DOW PHARMA) 29 February 1996 (1996-02-29) page 1, line 1-30 page 243, line 31-38 page 244, line 16-18	1-32
Y	WO 98 18785 A (SCHERING CORP) 7 May 1998 (1998-05-07) page 1, line 10-27 page 27; example 5 page 29; example 7 page 33, line 10-21 page 34; claim 1	1-32
A	EP 0 625 509 A (ZENECA LTD) 23 November 1994 (1994-11-23) page 2, line 1-22	1,23

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/21437

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9806394 A	19-02-1998	AU 3973397 A CN 1233179 A CZ 9900432 A EP 0920315 A NO 990706 A PL 331617 A	06-03-1998 27-10-1999 14-07-1999 09-06-1999 15-02-1999 02-08-1999
WO 9606094 A	29-02-1996	AT 177095 T AU 693936 B AU 3492895 A CA 2198084 A CN 1158612 A DE 69508093 D DE 69508093 T EP 0777666 A ES 2132709 T FI 970771 A GR 3030253 T HU 76644 A JP 10504580 T NO 970831 A NZ 292683 A ZA 9507033 A	15-03-1999 09-07-1998 14-03-1996 29-02-1996 03-09-1997 08-04-1999 15-07-1999 11-06-1997 16-08-1999 24-02-1997 31-08-1999 28-10-1997 06-05-1998 18-04-1997 28-07-1998 16-04-1996
WO 9818785 A	07-05-1998	US 5688960 A AU 4991697 A EP 0937064 A	18-11-1997 22-05-1998 25-08-1999
EP 0625509 A	23-11-1994	CA 2123636 A DE 69404549 D DE 69404549 T JP 6340624 A US 5521199 A	18-11-1994 04-09-1997 18-12-1997 13-12-1994 28-05-1996

THIS PAGE BLANK